Evolva SA, a Swiss biotech company with a genetic chemistry platform, is raising CHF 28 million in the first closing of a Series B financing that will support its planned takeover of Arpida Ltd, another Swiss biotech company. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
